Antibe Therapeutics Incwas A Biotechnology Company Based In Torontocanadafocused On Developing Safer Anti Inflammatory Drugs Through Hydrogen Sulfideha Sreleasing Technologyfounded In 2009The Company Aimed To Address Gastrointestinal Issues Linked To Nonsteroidal Anti Inflammatory Drugsnsaids It Was Publicly Traded On The Tsx Venture Exchange And Later Moved To The Toronto Stock Exchange In 2020 The Company Developed A Proprietary Ha S Releasing Platform To Modify Existing Nsaidsaiming To Reduce Gastrointestinal Ulcers And Bleeding While Maintaining Their Anti Inflammatory Effectsantibe S Lead Drugotenaproxesulcombined Naproxen With An Ha S Releasing Component And Was Cleared For U Sphase I Trials In 2021 After Positive Phase Ii Resultsthe Company Also Worked On Other Productsincluding Atb 352 And Therapies For Inflammatory Bowel Diseaseantibe Acquired Citagenix In 2015Which Specialized In Regenerative Medicine Products
